zinforo
pfizer ireland pharmaceuticals - ceftaroline fosamil - community-acquired infections; skin diseases, infectious; pneumonia - sýklalyf fyrir almenn nota, - zinforo is indicated for the treatment of the following infections in neonates, infants, children, adolescents and adults: , complicated skin and soft tissue infections (cssti), community-acquired pneumonia (cap) , consideration should be given to official guidance on the appropriate use of antibacterial agents.
amoxicillin comp alvogen (amoxin comp) filmuhúðuð tafla 875/125 mg
alvogen ehf. - amoxicillinum tríhýdrat; potassium clavulanate - filmuhúðuð tafla - 875/125 mg
amoxicillin sandoz mixtúruduft, dreifa 100 mg/ml
sandoz a/s* - amoxicillinum tríhýdrat - mixtúruduft, dreifa - 100 mg/ml
cefuroxim navamedic (cefuroxim villerton) stungulyfsstofn, lausn/dreifa 250 mg
navamedic asa - cefuroximum natríum - stungulyfsstofn, lausn/dreifa - 250 mg
ceftazidima normon (ceftazidime) stungulyfsstofn og leysir, lausn 1 g
laboratorios normon s.a. - ceftazidimum inn - stungulyfsstofn og leysir, lausn - 1 g
amoxin filmuhúðuð tafla 500 mg
ratiopharm gmbh* - amoxicillinum tríhýdrat - filmuhúðuð tafla - 500 mg
selexid filmuhúðuð tafla 400 mg
karo pharma ab* - pivmecillinamum hýdróklóríð - filmuhúðuð tafla - 400 mg
selexid filmuhúðuð tafla 200 mg
karo pharma ab* - pivmecillinamum hýdróklóríð - filmuhúðuð tafla - 200 mg
amoxin filmuhúðuð tafla 750 mg
ratiopharm gmbh* - amoxicillinum tríhýdrat - filmuhúðuð tafla - 750 mg
eficur vet. stungulyf, dreifa 50 mg/ml
laboratorios hipra s.a.* - ceftiofurum hýdróklóríð - stungulyf, dreifa - 50 mg/ml